Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

kidney disease and obstructive sleep apnea, though timing has not yet been announced for the additional studies. Amgen's monthly obesity drug matches competition in phase 2, but investors are ...

Amgen’s discovery pipeline has led the company to broaden its focus from oncology, immunology, and renal disease to include musculoskeletal, cardiovascular, and neurologic conditions.

Amgen’s discovery pipeline had led the company to broaden its focus from oncology, immunology, and renal disease to include musculoskeletal, cardiovascular, and neurologic conditions.

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Amgen’s focus on blood cell medications continued in the 2000s, with the approval of Aranesp for the treatment of anaemic patients with chronic renal failure, and the 2002 approval of Neulasta ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

As Chief Strategy Officer for Vifor Pharma, he created a joint renal-drug company between Vifor ... Springer also spent time in executive roles with Amgen. He sits on the board of multiple biotech ...